Longitudinal study on lung cancer using proteomics analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a longitudinal cohort for proteomics analysis in lung cancer patients by utilizing tissue and peripheral blood samples. It will focus on key treatment time points, including screening, postoperative efficacy prediction, and evaluation of therapeutic outcomes. The goal is to explore the potential of proteomics in distinguishing between benign and malignant lung conditions and assessing long-term prognosis. By analyzing protein profiles, the study seeks to enhance the understanding of lung cancer diagnosis and treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signing of the informed consent form;
2. Male or female, aged 18-75 years;
3. Patients with lung nodules confirmed by CT examination;
4. Good preoperative pulmonary function cooperation and complete reporting;
5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.

Exclusion Criteria:

1. Poor preoperative pulmonary function cooperation or missing reports;
2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
5. Coexisting with other severe functional impairments;
6. Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

Where it's running

• the First Affiliated of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jianxing He, Professor
• Email: drjiaxing.he@gmail.com
• Phone: 86-20-83337792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Precise Exercise Regimen for Cancer Care: a small pilot in stage II/III NSCLC

  This pilot tests the PERCC exercise program to see if it’s feasible for adults with stage II–III non-small cell lung cancer who are planned for neoadjuvant therapy and surgery.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07412041

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN

  This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.

  Recruiting at 12 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 11 other locations · NCT06051695

• Comparing brain radiotherapy timing in lung cancer patients with ALK rearrangements

  This study is testing whether a targeted lung cancer treatment called alectinib works better alone or with brain radiation for patients who have lung cancer with specific genetic changes and brain metastases.

  Recruiting at 3 sites Phase 1/2 Hoosier Cancer Research Network · Stanford, California and 2 other locations · NCT05987644

• Building a national network for lung cancer treatment in Italy

  This study is trying to create a nationwide network in Italy to gather information and improve treatments for advanced lung cancer patients using new therapies like immunotherapy.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT05550961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.